1 reporting a safe prolonged use of tedizolid after linezolidinduced myelotoxicity. We report here our experience of the rapid correction of linezolid-induced myelotoxicity after switching to tedizolid in three patients.
Sir, We read with interest the recently published manuscript by Yuste et al. 1 reporting a safe prolonged use of tedizolid after linezolidinduced myelotoxicity. We report here our experience of the rapid correction of linezolid-induced myelotoxicity after switching to tedizolid in three patients.
The first patient was a man in his 80s, with a previous history of ethmoidectomy for ethmoidal cancer, admitted for neurological impairment. Cerebral CT revealed a frontal parenchymal abscess. Empirical treatment was initiated with meropenem (intravenous, 2 g/8 h) and linezolid (600 mg/12 h). Since microbiological samples remained sterile, this antibiotic regimen was continued. His neurological status slowly improved. The cerebral CT scan 19 days after the initiation of this treatment exhibited a decrease in abscess size. However, after 20 days of linezolid, the platelet count started to decrease with a nadir of 83%10 9 /L at day 24. Haemoglobin count decreased as well and the patient received an erythrocyte transfusion. Due to haematological toxicity, linezolid was switched to oral tedizolid (200 mg a day) at day 23. The platelet count normalized (.150%10 9 /L) after 10 days of tedizolid ( Figure 1 ). The antibiotic therapy was stopped at week 12, including 9 weeks of tedizolid without clinical or biological side effects. The platelet count remained above 150%10 9 /L throughout the remainder of the tedizolid treatment period.
The second patient was a man in his 60s, treated with linezolid for a prosthetic vascular graft infection caused by multiresistant Staphylococcus epidermidis (linezolid MIC " 1 mg/L). Due to his poor general health status, it was decided to delay the prosthetic replacement until after a prolonged antibiotic treatment. At day 58, linezolid was interrupted because of a platelet count of 83%10 9 /L and linezolid was switched to daptomycin. The platelet count normalized 10 days after linezolid interruption. Daptomycin was then switched to oral tedizolid. The platelet count was 244%10 9 /L and remained above 150%10 9 /L throughout the tedizolid treatment period; at the end of treatment, after 88 days of tedizolid, the platelet count was 164%10 9 /L. The third patient was a man in his 80s with a history of prosthetic hip infection caused by MSSA and multiresistant S. epidermidis (linezolid MICs were 2 and 1 mg/L, respectively). Along with prosthetic replacement, antibiotic treatment with levofloxacin, rifampicin and linezolid was initiated. Linezolid was stopped at day 30 and switched to tedizolid, due to a haemoglobin level of 8.5 g/dL and a reticulocyte count of 10%10 9 /L. Tedizolid was then continued for 10 days; 10 days after the switch, the haemoglobin level was 10.4 g/dL and the reticulocyte count was 174%10 9 /L. Tedizolid and linezolid are two oxazolidinone antibacterials active against a wide range of Gram-positive bacteria. The most frequently described side effect with linezolid is myelotoxicity, especially thrombocytopenia, occurring most of the time after 7-14 days of treatment. 2 Tedizolid is a new oxazolidinone antibacterial currently approved in the treatment of acute bacterial skin and skin-structure infections. In the two Phase 3 clinical trials ESTABLISH-1 and ESTABLISH-2, assessing the non-inferiority of tedizolid versus linezolid in acute skin bacterial infections, a lower incidence of thrombocytopenia was reported in the tedizolid group. However, the duration of treatment was short in both groups (6 days for tedizolid and 10 days for linezolid). 3 We report three cases of linezolid-induced myelotoxicity, with rapid correction after immediate switch to tedizolid in two cases and the absence of subsequent toxicity after a delayed switch in 1 performed a 26 day washout period without linezolid before introduction of tedizolid. Interestingly, in two cases, though we immediately introduced tedizolid after linezolid interruption, we noted the rapid correction of myelotoxicity and no subsequent new toxicity despite a prolonged use of tedizolid (9 and 12 weeks, respectively) for two patients.
The myelotoxicity of oxazolidinones is not well explained, but seems to be linked to mitochondrial toxicity. Since tedizolid exhibits a greater, but shorter, inhibition of mitochondrial protein synthesis than linezolid, this, combined with a lower total daily dose (200 mg daily versus 1200 mg daily), could explain the noticeable absence of myelotoxicity for tedizolid at current doses. 4, 5 Indeed, a recent study in healthy subjects has shown that higher daily doses of tedizolid (300 and 400 mg daily) seem to induce thrombocytopenia as frequently as linezolid. 6 Finally, microbiological cure was obtained with tedizolid for the two infections that were documented.
Other works will have to confirm the long-term haematological safety of tedizolid, but we believe there is no need for any washout period after linezolid-induced myelotoxicity, as demonstrated in two of our three patients.
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Sir, We previously reported our experience in nine HIV-infected patients on dolutegravir monotherapy, naive to HAART and with a zenith HIV-RNA ,100 000 copies/mL. 1 We now report the results of an extended follow-up in 20 antiretroviral-naive HIV-1-infected patients with a zenith HIV-RNA ,100 000 copies/mL who started Linezolid was switched to tedizolid at day 23. There was no other therapeutic modification during the thrombocytopenia phase.
